New drug combinations for KRAS- or BRAF-driven lung cancer
Studying the initiation, progression and therapy of lung cancer in mouse models
['FUNDING_R01'] · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · NIH-11235830
Developing new combination drug approaches to help people with lung cancers caused by KRAS or BRAF mutations who need better treatment options.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH (nih funded) |
| Locations | 1 site (SALT LAKE CITY, UNITED STATES) |
| Trial ID | NIH-11235830 on ClinicalTrials.gov |
What this research studies
Researchers use mouse models that carry the same KRAS or BRAF mutations found in some people's lung tumors to study how cancers start, grow, and resist treatment. They test combinations of targeted drugs and immunotherapy in these models to find treatments that shrink tumors or prevent resistance. Lab studies will also look for biomarkers that predict which tumors respond to specific combinations. Promising results would be moved toward clinical testing to benefit patients.
Who could benefit from this research
Good fit: People with lung cancer whose tumors carry KRAS or BRAF driver mutations, especially KRASG12C or BRAFV600E, are the most likely candidates for therapies coming from this work.
Not a fit: Patients whose tumors lack KRAS or BRAF driver mutations, or those whose care is limited to standard surgery or radiation, are unlikely to receive direct benefit from this mouse-model research.
Why it matters
Potential benefit: Could identify combination therapies and biomarkers that lead to more effective, personalized treatments for patients with KRAS- or BRAF-mutant lung cancer.
How similar studies have performed: Targeted drugs such as sotorasib for KRASG12C and dabrafenib plus trametinib for BRAFV600E have helped some patients, but many mutation-defined groups still need better combination treatments.
Where this research is happening
SALT LAKE CITY, UNITED STATES
- UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH — SALT LAKE CITY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MCMAHON, MARTIN — UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH
- Study coordinator: MCMAHON, MARTIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.